This trial is terminated!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer or Stage IV Renal Cell Cancer
and you are
over 18
years old
Phase
-
The phase for this study is not defined.
Show me locations

The purpose

The purpose of this study is to find out what effects pazopanib (pazopanib hydrochloride) (also called Votrient®) may have on MRI (magnetic resonance imaging) scans, blood pressure, and various proteins in the blood. Pazopanib is Food and Drug Administration (FDA) approved for treating renal cell cancer. It is an agent that prevents angiogenesis, which is new blood vessel formation. The use of pazopanib described in this study is a standard of care, but the additional MRI and blood tests that will be performed are experimental

Provided treatments

  • Drug: pazopanib hydrochloride
  • Other: laboratory biomarker analysis
  • Procedure: dynamic contrast-enhanced magnetic resonance imaging
  • Other: pharmacogenomic studies
Tris trial is registered with FDA with number: NCT01599832. The sponsor of the trial is University of Chicago and it is looking for 20 volunteers for the current phase.
Official trial title:
DCE-MRI as Pazopanib Biomarker in Metastatic Renal Cancer